Recent Material Events - Quest Group Intl (QSTG)

Filing Date	Description
2008-08-11	Series A preferred stock, $.001 par value, 1,000,000 shares designated, no shares issued and outstanding ...
2008-05-08	Series A preferred stock, $.001 par value, 1,000,000 shares designated, no shares issued and outstanding ...
2008-03-24	On March 24, 2008, NuRx Pharmaceuticals, Inc. (the “ Company ”) announced that it has dosed the first patient in a Phase I clinical trial of first-in-class rexinoid receptor (RXR) agonist NRX4204 . A copy of the press release is ...
2007-12-28	Since our inception in 2001, we have been in the business of selling nutritional products. As a result of the entering into of a license agreement with Vitae, we spun off this business and began to pursue a new business plan in the pharmaceutica ...
2007-11-30	On November 27, 2007, Matt Borenzweig was appointed to serve as a director of NuRx Pharmaceuticals, Inc. (the “Company”) for a term expiring at the next annual meeting of stockholders. Mr. Borenzweig has been senior vice president of ...
2007-09-21	Steven Gershick was appointed as the Chief Financial Officer of the Company by the Board of Directors on September 20, 2007. Mr. Gershick, age 52, has served as a consultant to the Company since June 1, 2007. Mr. Gershick will serve the Company ...
2006-11-08	Prior to the closing of the Acquisition, the Company would be required to increase its authorized common stock to 150,000,000 shares of Common Stock and 5,000,000 shares of preferred stock. In addition, the Company would be required to reduce the num... ...
2006-10-26	Material event, click here to read
2005-04-07	Material event, click here to read